LIVIVO - The Search Portal for Life Sciences

zur deutschen Oberfläche wechseln
Advanced search

Search results

Result 1 - 10 of total 118

Search options

  1. Article: [New development in bisphosphonate treatment. Review of effect on bone metabolism by minodronic acid in primary osteoporosis].

    Fukunaga, Masao

    Clinical calcium

    2009  Volume 19, Issue 1, Page(s) 63–73

    Abstract: Minodronic acid hydrate is a novel bisphosphonate with stronger anti-resorptive effects, compared to the other existing bisphosphonates. We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on ... ...

    Abstract Minodronic acid hydrate is a novel bisphosphonate with stronger anti-resorptive effects, compared to the other existing bisphosphonates. We performed additional analyses of phase III clinical trial and compared the effect of minodronic acid hydrate on bone turnover markers with those of alendronate in primary osteoporosis. The results showed that minodronic acid hydrate suppressed bone turnover early after treatment, and it also was effective in the treatment of patients with prevalent vertebral fracture, which is a high risk for subsequent fracture.
    MeSH term(s) Alendronate/pharmacology ; Alendronate/therapeutic use ; Amino Acids/urine ; Biomarkers/urine ; Bone Density Conservation Agents/pharmacology ; Bone Density Conservation Agents/therapeutic use ; Bone and Bones/metabolism ; Clinical Trials, Phase III as Topic ; Collagen Type I/urine ; Diphosphonates/pharmacology ; Diphosphonates/therapeutic use ; Fractures, Spontaneous/etiology ; Fractures, Spontaneous/prevention & control ; Humans ; Imidazoles/pharmacology ; Imidazoles/therapeutic use ; Osteoporosis/diagnosis ; Osteoporosis/drug therapy ; Osteoporosis/metabolism ; Peptides/urine
    Chemical Substances Amino Acids ; Biomarkers ; Bone Density Conservation Agents ; Collagen Type I ; Diphosphonates ; Imidazoles ; Peptides ; collagen type I trimeric cross-linked peptide ; YM 529 (127657-42-5) ; deoxypyridinoline (90032-33-0) ; Alendronate (X1J18R4W8P)
    Language Japanese
    Publishing date 2009-01
    Publishing country Japan
    Document type Comparative Study ; English Abstract ; Journal Article ; Review
    ZDB-ID 2386417-5
    ISSN 0917-5857
    ISSN 0917-5857
    DOI CliCa09016373
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6536: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  2. Article: [Hyperostosis].

    Fukunaga, Masao

    Nihon rinsho. Japanese journal of clinical medicine

    2006  Volume Suppl 2, Page(s) 156–159

    MeSH term(s) Anti-Inflammatory Agents/therapeutic use ; Diagnosis, Differential ; Diagnostic Imaging ; Diphosphonates/therapeutic use ; Humans ; Hyperostosis/diagnosis ; Hyperostosis/pathology ; Hyperostosis/physiopathology ; Hyperostosis/therapy ; Prognosis
    Chemical Substances Anti-Inflammatory Agents ; Diphosphonates
    Language Japanese
    Publishing date 2006-06-28
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 429: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  3. Book: Kotsu soshōshō no shindan to kanbetsu

    Fukunaga, Masao

    kotsu mitsudo sokutei to sekitsui gazō shindan

    2005  

    Abstract: A number of experts explain diagnostic imaging, essential in diagnosing spinal disorders and measuring bone density. Describes bone strength and bone morphology necessary in understanding osteoporosis. ...

    Author's details Fukunaga Masao hen
    Abstract A number of experts explain diagnostic imaging, essential in diagnosing spinal disorders and measuring bone density. Describes bone strength and bone morphology necessary in understanding osteoporosis.
    MeSH term(s) Osteoporosis/diagnosis ; Osteoporosis/diagnostic imaging ; Radiography
    Language Japanese
    Size 314 p. :, ill.
    Edition Shohan.
    Publisher Iyaku Jānarusha
    Publishing place Ōsaka
    Document type Book
    ISBN 9784753221257 ; 4753221253
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  4. Article ; Online: Impact of bone mineral density in reducing fracture risk in patients receiving alendronate plus alfacalcidol therapy.

    Itoi, Eiji / Uemura, Yukari / Ohta, Hiroaki / Nakamura, Toshitaka / Fukunaga, Masao / Orimo, Hajime / Shiraki, Masataka

    Journal of orthopaedic science : official journal of the Japanese Orthopaedic Association

    2020  Volume 26, Issue 6, Page(s) 1085–1093

    Abstract: Backgroud: Changes in bone mineral density (BMD) are a potential surrogate marker for fracture endpoints in clinical trials. However little is known whether the increase in BMD in response to combination treatment with alendronate plus alfacalcidol is ... ...

    Abstract Backgroud: Changes in bone mineral density (BMD) are a potential surrogate marker for fracture endpoints in clinical trials. However little is known whether the increase in BMD in response to combination treatment with alendronate plus alfacalcidol is associated with fracture risk reduction. We aimed to evaluate the impact of BMD on fracture risk in osteoporosis patients, using the data from the randomized clinical trial comparing alendronate plus alfacalcidol with alendronate alone.
    Methods: We selected 412 patients with two or more prevalent vertebral fractures and who had BMD measurements at baseline and after 6, 12, and/or 24 months out of 2022 patients from the database of the Japanese Osteoporosis Intervention Trial. Patients in this subset who received combination treatment with alendronate plus alfacalcidol had shown a lower risk of fracture than patients treated with alendronate alone. We used Poisson regression model analysis to calculate the proportion of treatment effect (PTE) that was attributable to BMD increases in patients receiving combination treatment.
    Results: The highest PTE attributable to changes in BMD was 1.2% in patients with a BMD increase of 3% or more in the lumbar spine. For BMD measurements of the radius, the highest PTE was 2.8% with a BMD increase of 0% or more. For BMD measurements of the metacarpal bone, the highest PTE was 1.2% with a BMD increase of 3% or more. In patients with a BMD greater than or equal to 70% of the young adult mean in the lumbar spine, the PTE attributable to BMD was 0.2%. In patients with a BMD greater than or equal to 70% of the young adult mean in the radius, the PTE attributable to BMD was 0.3%.
    Conclusions: The additional effects of alfacalcidol in reducing fracture risk do not likely result from increased BMD; other mechanisms remain a possibility.
    MeSH term(s) Alendronate/therapeutic use ; Bone Density ; Bone Density Conservation Agents/therapeutic use ; Female ; Humans ; Hydroxycholecalciferols ; Osteoporosis, Postmenopausal ; Young Adult
    Chemical Substances Bone Density Conservation Agents ; Hydroxycholecalciferols ; alfacalcidol (URQ2517572) ; Alendronate (X1J18R4W8P)
    Language English
    Publishing date 2020-12-23
    Publishing country Japan
    Document type Journal Article ; Randomized Controlled Trial
    ZDB-ID 1314243-4
    ISSN 1436-2023 ; 0949-2658
    ISSN (online) 1436-2023
    ISSN 0949-2658
    DOI 10.1016/j.jos.2020.10.017
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 4484: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (2.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  5. Article ; Online: Effect of Bone Resorption Inhibitors on Serum Cholesterol Level and Fracture Risk in Osteoporosis: Randomized Comparative Study Between Minodronic Acid and Raloxifene.

    Ohta, Hiroaki / Uemura, Yukari / Sone, Teruki / Tanaka, Shiro / Soen, Satoshi / Mori, Satoshi / Hagino, Hiroshi / Fukunaga, Masao / Nakamura, Toshitaka / Orimo, Hajime / Shiraki, Masataka

    Calcified tissue international

    2023  Volume 112, Issue 4, Page(s) 430–439

    Abstract: The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum ... ...

    Abstract The positive link between osteoporosis and hypercholesterolemia has been documented, and bone resorption inhibitors, such as nitrogen-containing bisphosphonates (N-BP) and selective estrogen receptor modulators (SERMs), are known to reduce serum cholesterol levels. However, the relationship between the baseline cholesterol level and incident fracture rate under the treatment using the bone resorption inhibitors has not been documented. We investigated the relation between vertebral fracture incident and the baseline cholesterol levels and cholesterol-lowering effect of N-BP and SERM in osteoporosis through a prospective randomized open-label study design. Patients with osteoporosis (n = 3986) were allocated into two groups based on the drug used for treatment: minodronic acid (MIN) (n = 1624) as an N-BP and raloxifene (RLX) as an SERM (n = 1623). Serum levels of cholesterol and incidence of vertebral fracture were monitored for 2 years. The vertebral fracture rates between the two groups were compared using the pre-specified stratification factors. The patients receiving MIN with baseline low-density lipoprotein (LDL)-cholesterol level of ≥ 140 mg/dL, high-density lipoprotein cholesterol level < 40 mg/dL, age group of ≥ 75 years, and T score of BMD ≥ -3 SD had significantly lower vertebral fracture rates than those receiving RLX (incidence rate ratios (IRR) 0.45 [95% confidence interval (CI) 0.30 0.75, p = 0.001], 0.25 [95% CI 0.09 0.65, p = 0.005], 0.71 [95% CI 0.56 0.91, p = 0.006], 0.47 [95% CI 0.30 0.75, p = 0.0012], respectively). The cholesterol-lowering effect was stronger in the RLX group than in the MIN group, regardless of prior statin use. These results indicated that MIN treatment was more effective in reducing fracture risk in patients with higher LDL cholesterol levels, although its cholesterol-lowering ability was lesser than the RLX treatment.Trial registration University Hospital Medical Information Network-Clinical Trials Registry (UMIN-CTR), No. UMIN000005433; date: April 13, 2011.
    MeSH term(s) Humans ; Aged ; Female ; Raloxifene Hydrochloride/pharmacology ; Raloxifene Hydrochloride/therapeutic use ; Bone Density Conservation Agents/therapeutic use ; Bone Density Conservation Agents/pharmacology ; Selective Estrogen Receptor Modulators/pharmacology ; Selective Estrogen Receptor Modulators/therapeutic use ; Spinal Fractures/complications ; Prospective Studies ; Bone Density ; Osteoporosis/complications ; Osteoporosis/drug therapy ; Fractures, Bone/etiology ; Cholesterol ; Osteoporosis, Postmenopausal/drug therapy
    Chemical Substances Raloxifene Hydrochloride (4F86W47BR6) ; Bone Density Conservation Agents ; Selective Estrogen Receptor Modulators ; Cholesterol (97C5T2UQ7J)
    Language English
    Publishing date 2023-01-28
    Publishing country United States
    Document type Randomized Controlled Trial ; Journal Article ; Research Support, Non-U.S. Gov't
    ZDB-ID 304266-2
    ISSN 1432-0827 ; 0944-0747 ; 0008-0594 ; 0171-967X
    ISSN (online) 1432-0827
    ISSN 0944-0747 ; 0008-0594 ; 0171-967X
    DOI 10.1007/s00223-023-01060-9
    Database MEDical Literature Analysis and Retrieval System OnLINE

    Full text online

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 317: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  6. Book: Saishin kotsuen teiryōhō

    Fukunaga, Masao

    kiso kara rinshō made

    2004  

    Title translation Quantitative analysis of bone mineral.
    Author's details Fukunaga Masao kanshū
    MeSH term(s) Bone Density/physiology ; Densitometry/methods
    Language Japanese
    Size 262 p. :, ill.
    Edition Dai 1-pan.
    Publisher Medikarurebyūsha
    Publishing place Tōkyō
    Document type Book
    ISBN 9784896007428 ; 4896007425
    Database Catalogue of the US National Library of Medicine (NLM)

    More links

    Kategorien

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

    Inter-library loan at ZB MED

    Your chosen title can be delivered directly to ZB MED Cologne location if you are registered as a user at ZB MED Cologne.

  7. Article: [Bone quality and bone metabolism (marker)].

    Fukunaga, Masao

    Clinical calcium

    2004  Volume 14, Issue 4, Page(s) 561–565

    Abstract: NIH Consensus Development Panel states that bone strength primarily reflects the integration of bone density and bone quality. In addition, it is reported that bone quality refers to architecture, turnover, damage accumulation, and mineralization. ... ...

    Abstract NIH Consensus Development Panel states that bone strength primarily reflects the integration of bone density and bone quality. In addition, it is reported that bone quality refers to architecture, turnover, damage accumulation, and mineralization. Increased bone turnover is an independent risk of fracture of low bone mineral density. Increased bone turnover of urinary CTX, free DPD and free PYD, or decreased turnover of serum ICTP leads to increased relative risk of fractures in the femoral neck or spine/non-spine. Reduction of 50-70% in bone metabolic markers with therapy reduces fracture risk by 40-44%.
    MeSH term(s) Biomarkers/analysis ; Bone and Bones/metabolism ; Bone and Bones/physiology ; Humans
    Chemical Substances Biomarkers
    Language Japanese
    Publishing date 2004-04
    Publishing country Japan
    Document type English Abstract ; Journal Article ; Review
    ZDB-ID 2386417-5
    ISSN 0917-5857
    ISSN 0917-5857
    DOI CliCa0404561565
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 6536: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 2021: Bestellungen von Artikeln über das Online-Bestellformular
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  8. Article: [VERT(Vertebral Efficacy with Risedronate Therapy)-MN(Multinational) Study and VERT-NA(North America) Study].

    Fukunaga, Masao

    Nihon rinsho. Japanese journal of clinical medicine

    2004  Volume 62 Suppl 2, Page(s) 433–436

    MeSH term(s) Aged ; Bone Density ; Etidronic Acid/analogs & derivatives ; Etidronic Acid/therapeutic use ; Female ; Humans ; Middle Aged ; Multicenter Studies as Topic ; Osteoporosis/complications ; Osteoporosis/drug therapy ; Osteoporosis/physiopathology ; Randomized Controlled Trials as Topic ; Risedronate Sodium ; Risk ; Spinal Fractures/etiology ; Spinal Fractures/prevention & control
    Chemical Substances Etidronic Acid (M2F465ROXU) ; Risedronate Sodium (OFG5EXG60L)
    Language Japanese
    Publishing date 2004-02
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 429: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  9. Article: [Bone mass measurement and evaluation of therapeutical response].

    Fukunaga, Masao

    Nihon rinsho. Japanese journal of clinical medicine

    2004  Volume 62 Suppl 2, Page(s) 273–277

    MeSH term(s) Absorptiometry, Photon ; Aging/physiology ; Alendronate/therapeutic use ; Biomarkers ; Bone Density ; Calcium/therapeutic use ; Estrogen Replacement Therapy ; Etidronic Acid/therapeutic use ; Fractures, Bone/prevention & control ; Humans ; Menopause/physiology ; Monitoring, Physiologic ; Osteoporosis/diagnosis ; Osteoporosis/drug therapy ; Osteoporosis/physiopathology ; Quality of Life ; Risk ; Sensitivity and Specificity ; Treatment Outcome ; Vitamin D/therapeutic use
    Chemical Substances Biomarkers ; Vitamin D (1406-16-2) ; Etidronic Acid (M2F465ROXU) ; Calcium (SY7Q814VUP) ; Alendronate (X1J18R4W8P)
    Language Japanese
    Publishing date 2004-02
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 429: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

  10. Article: [N-terminal crosslinking telopeptide of type I collagen].

    Fukunaga, Masao

    Nihon rinsho. Japanese journal of clinical medicine

    2004  Volume 62 Suppl 12, Page(s) 236–239

    MeSH term(s) Biomarkers/blood ; Biomarkers/urine ; Bone Density ; Bone Neoplasms/diagnosis ; Bone Neoplasms/secondary ; Bone Resorption/diagnosis ; Collagen/blood ; Collagen/urine ; Collagen Type I ; Enzyme-Linked Immunosorbent Assay ; Osteoporosis/diagnosis ; Osteoporosis/physiopathology ; Peptides/blood ; Peptides/urine ; Reference Values ; Specimen Handling
    Chemical Substances Biomarkers ; Collagen Type I ; Peptides ; collagen type I trimeric cross-linked peptide ; Collagen (9007-34-5)
    Language Japanese
    Publishing date 2004-12
    Publishing country Japan
    Document type Journal Article ; Review
    ZDB-ID 390903-7
    ISSN 0047-1852
    ISSN 0047-1852
    Database MEDical Literature Analysis and Retrieval System OnLINE

    More links

    Kategorien

    In stock of ZB MED Cologne/Königswinter

    Zs.A 429: Show issues Location:
    Je nach Verfügbarkeit (siehe Angabe bei Bestand)
    bis Jg. 1994: Bestellungen von Artikeln über das Online-Bestellformular
    Jg. 1995 - 2021: Lesesall (1.OG)
    ab Jg. 2022: Lesesaal (EG)

    Order via subito

    This service is chargeable due to the Delivery terms set by subito. Orders including an article and supplementary material will be classified as separate orders. In these cases, fees will be demanded for each order.

To top